Navigation Links
Novavax CEO to Present at Phacilitate Vaccine Forum Barcelona 2009
Date:6/18/2009

ROCKVILLE, Md., June 18 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX) a clinical-stage vaccine company, announced today that Dr. Rahul Singhvi, President and Chief Executive Officer, will be presenting at the Phacilitate Vaccine Forum Barcelona 2009 conference on June 22 and June 23, 2009 at The Fira Palace, Barcelona, Spain. Dr. Singhvi is participating in the Panel Session 'How are VLP based vaccines helping to shape the manufacturing processes of the future?' and will also be speaking to the Case Study: Highlighting the clinical milestones to date: What progress is being made with respect to immune response in healthy adults? Presentations will be available on www.novavax.com after the event.

ABOUT NOVAVAX

Novavax, Inc. (Nasdaq: NVAX) is a clinical stage biotechnology company, creating novel vaccines, including H1N1, to address a broad range of infectious diseases worldwide using advanced proprietary virus-like particle (VLP) technology. The Company produces these VLP based, potent, recombinant vaccines utilizing new and efficient manufacturing approaches. Additional information about Novavax is available at www.novavax.com and in the Company's various filings with the Securities and Exchange Commission.

Forward-Looking Statement

Statements herein relating to future development results and performance, conditions or strategies and other matters, including expectations regarding product and clinical developments, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act. Novavax cautions that these for
'/>"/>

SOURCE Novavax, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Novavax and the NIH Agree to Evaluate a Virus-like Particle (VLP) Vaccine Candidate Against the Novel Influenza A (H1N1) Virus
2. Novavax Reports First Quarter 2009 Financial Results
3. Novavax Announces Enrollment in the Second Phase II Study of its Seasonal Influenza VLP Vaccine Candidate
4. Novavax Announces Release Date of 2009 First Quarter, Financial Results and Investor Conference Call
5. Novavax Announces Early Retirement of $17 Million of Convertible Debt
6. NOVAVAX Announces Publication of a Preclinical Study Demonstrating that a Virus-like Particle Vaccine Provided Protection Against Highly Pathogenic H1N1 and H5N1 Influenza Strains
7. Novavax Announces New Capital Infusion Through a Strategic Alliance with Cadila Pharmaceuticals of India
8. Novavax Announces New Release Date of 2008 Fourth Quarter Financial Results and Investor Conference Call
9. Novavax Announces Release Date of 2008 Fourth Quarter Financial Results and Investor Conference Call
10. Novavax to Present at Cowen and Company 29th Annual Healthcare Conference
11. NOVAVAX Announces Preclinical Study Results for a Respiratory Syncytial Virus (RSV) Vaccine Candidate Directed Against the Fusion (F) Protein
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... 4, 2015 GliaCure, a privately-held biotechnology ... for neurological and neuropsychiatric disorders based on glial ... Alzheimer,s patients in a Phase 1b clinical trial ... developed as a potential disease-modifying treatment. GliaCure,s innovative ... that it both promotes the clearance of amyloid ...
(Date:5/4/2015)... - Fluorinov Pharma (Fluorinov), a FACIT portfolio company, ... Roger J Garceau, to its Board of Directors. ... including corporate development and clinical strategy, his appointment ... expertise as Fluorinov transitions to clinical development.  ... pharmaceutical development experience to Fluorinov and most recently ...
(Date:5/4/2015)... 2015 Genedata, a leading provider ... life science research, today announced the release of ... of its enterprise solution for biologics R&D. This ... efficient discovery and development of novel biotherapeutics. Version ... address protein optimization and developability requirements. Genedata will ...
(Date:5/4/2015)... HONG KONG , May 4, 2015 ... or the "Company"), China,s leading ... cell processing and stem cell storage services, today announced ... Holdings Limited ("Golden Meditech"), a Hong Kong ... the Company, has entered into an agreement (the "Agreement") ...
Breaking Biology Technology:GliaCure Initiates Phase 1b Dosing in Alzheimer's Patients 2Roger J Garceau joins Fluorinov board, adds clinical expertise to bromodomain program and oncology pipeline 2Roger J Garceau joins Fluorinov board, adds clinical expertise to bromodomain program and oncology pipeline 3Genedata Biologics 5.0 – Antibody Engineering and Developability Assessment Advances 2Genedata Biologics 5.0 – Antibody Engineering and Developability Assessment Advances 3Genedata Biologics 5.0 – Antibody Engineering and Developability Assessment Advances 4China Cord Blood Corporation Receives Notice of a Transaction Regarding its 7% Senior Convertible Notes Due 2017 Held by KKR 2China Cord Blood Corporation Receives Notice of a Transaction Regarding its 7% Senior Convertible Notes Due 2017 Held by KKR 3
... -- 3SBio Inc. (NASDAQ: SSRX ) ... company focused on researching, developing, manufacturing and marketing ... its first quarter 2011 unaudited financial results after ... 11, 2011 at 8:00pm (US Eastern ). ...
... that a new market research report is available in ... Global Markets http://www.reportlinker.com/p0488650/Medical-Enzymes-Technologies-and-Global-Markets.html ... growing. The global market for medical enzymes is estimated ... at a compound annual growth rate (CAGR) of 3.9%, ...
... Novavax, Inc. (Nasdaq: NVAX ) will report financial ... 9, 2011, before the U.S. financial markets open.  The announcement ... by Stanley C. Erck, President and Chief Executive Officer, and ... The webcast and conference call will be ...
Cached Biology Technology:3SBio Inc. Schedules Unaudited First Quarter 2011 Results 2Reportlinker Adds Medical Enzymes: Technologies and Global Markets 2Reportlinker Adds Medical Enzymes: Technologies and Global Markets 3Reportlinker Adds Medical Enzymes: Technologies and Global Markets 4Reportlinker Adds Medical Enzymes: Technologies and Global Markets 5Reportlinker Adds Medical Enzymes: Technologies and Global Markets 6Reportlinker Adds Medical Enzymes: Technologies and Global Markets 7Reportlinker Adds Medical Enzymes: Technologies and Global Markets 8Reportlinker Adds Medical Enzymes: Technologies and Global Markets 9Reportlinker Adds Medical Enzymes: Technologies and Global Markets 10Reportlinker Adds Medical Enzymes: Technologies and Global Markets 11Reportlinker Adds Medical Enzymes: Technologies and Global Markets 12Reportlinker Adds Medical Enzymes: Technologies and Global Markets 13
(Date:4/14/2015)... April 14, 2015  HYPR Corp. today announced ... ® ) Alliance tm , an industry consortium ... commit to share technology and collaborate to deliver ... interoperable, more secure and private, and easier to ... verification that protects sensitive user information and eliminates ...
(Date:4/13/2015)... April 13, 2015  higi, a leading cloud-based consumer ... more fully engage with their communities around health and ... protected and secure API.  ... most accessible, affordable, and convenient vehicle to receive validated ... The API will allow higi,s trusted ...
(Date:4/8/2015)... N.C. , April 8, 2015  Infinisource, ... solutions and services, and Morpho, a leading supplier ... partnership to produce the market,s most advanced biometrically-enabled ... Infinisource,s iSolved NXG time clock is setting a ... and labor data for the small and mid-size ...
Breaking Biology News(10 mins):HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 2higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 3iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 3
... of life, and occurs naturally in soil and ground water ... has been linked to lung, bladder and kidney cancer, and ... in drinking water. Chemically similar to phosphorus, arsenic forms arsenate ... 4 3- ). Arsenate interferes with many phosphate-requiring metabolic ...
... April 8 to 10, 2010, 185 attendees from 25 ... new tools to humanely and effectively manage populations of ... biology and other related scientific disciplines presented the newest ... health drug development. Veterinary leaders joined with animal welfare ...
... CORVALLIS, Ore. Forestry scientists at Oregon State University ... rate and other characteristics of trees can be changed ... is conceptually similar to traditional plant breeding. Cisgenics ... sexually compatible. If governments choose to regulate it similarly ...
Cached Biology News:Arsenic hyperaccumulating ferns: How do they survive? 2Arsenic hyperaccumulating ferns: How do they survive? 3Momentum builds after 4th International Symposium on Pet Contraception 2Momentum builds after 4th International Symposium on Pet Contraception 3Success with 'cisgenics' in forestry offers new tools for biotechnology 2Success with 'cisgenics' in forestry offers new tools for biotechnology 3
D.R. Harper (1993) • Includes: essential information on taxonomy, culture and safe handling of viruses, immunology, monoclonal antibodies, antivirals and vaccines....
...
Performance, mycoplasma, virus, and endotoxin tested. Collected from calves 14 days old or less...
...
Biology Products: